Medexus Pharmaceuticals Inc. (MEDXF)
OTCMKTS
· Delayed Price · Currency is USD
3.700
+0.900 (32.14%)
Jan 22, 2025, 12:35 PM EST
Medexus Pharmaceuticals Revenue
Medexus Pharmaceuticals had revenue of $26.30M in the quarter ending September 30, 2024, a decrease of -13.27%. This brings the company's revenue in the last twelve months to $104.76M, down -12.15% year-over-year. In the fiscal year ending March 31, 2024, Medexus Pharmaceuticals had annual revenue of $113.05M with 4.59% growth.
Revenue (ttm)
104.76M
Revenue Growth
-12.15%
P/S Ratio
n/a
Revenue / Employee
1.28M
Employees
82
Market Cap
68.71M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 113.05M | 4.96M | 4.59% |
Mar 31, 2023 | 108.10M | 31.40M | 40.93% |
Mar 31, 2022 | 76.70M | -2.96M | -3.71% |
Mar 31, 2021 | 79.66M | 24.15M | 43.52% |
Mar 31, 2020 | 55.51M | 21.64M | 63.91% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
Veradigm | 1.53B |
SS Innovations International | 16.04M |
Elite Pharmaceuticals | 71.17M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
BioStem Technologies | 210.49M |
Silence Therapeutics | 21.77M |
Medexus Pharmaceuticals News
- 2 hours ago - Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update - Newsfile Corp
- 7 days ago - Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada - Newsfile Corp
- 2 months ago - Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada - Newsfile Corp
- 2 months ago - Medexus Pharmaceuticals Inc. (MEDXF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Medexus Announces Strong Fiscal Q2 2025 Results - Newsfile Corp
- 3 months ago - Medexus Schedules Second Fiscal Quarter 2025 Conference Call - Newsfile Corp
- 4 months ago - Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors - Newsfile Corp
- 4 months ago - Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date - Newsfile Corp